Compare TCI & TKNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TCI | TKNO |
|---|---|---|
| Founded | 1983 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 349.1M | 308.3M |
| IPO Year | 1994 | 2021 |
| Metric | TCI | TKNO |
|---|---|---|
| Price | $41.18 | $4.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.7K | ★ 137.9K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 135.29 | 43.86 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $49,060,000.00 | $40,520,000.00 |
| Revenue This Year | N/A | $8.27 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | $2,020.50 | ★ N/A |
| Revenue Growth | 4.23 | ★ 7.35 |
| 52 Week Low | $31.48 | $1.91 |
| 52 Week High | $59.65 | $6.68 |
| Indicator | TCI | TKNO |
|---|---|---|
| Relative Strength Index (RSI) | 46.74 | 45.14 |
| Support Level | $34.92 | $5.00 |
| Resistance Level | $42.02 | $5.88 |
| Average True Range (ATR) | 1.79 | 0.38 |
| MACD | -0.79 | -0.08 |
| Stochastic Oscillator | 37.10 | 23.33 |
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates in two business segments: the acquisition, development, ownership and management of multifamily properties; and the acquisition, development, ownership and management of commercial properties; which are office properties. The services for its commercial segment include rental of office space and other tenant services, including parking and storage space rental. The services for its multifamily segment include rental of apartments and other tenant services, including parking and storage space rental. the company derives maximum revenue from Multifamily Segment.
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.